Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

<p>PTEN and RB loss in HGSOC. <b>A,</b> Frequency of loss of PTEN protein expression across HRR-centric subtypes. <b>B,</b> Frequency of loss of RB protein expression across HRR-centric subtypes. <b>C,</b> Impact of RB loss on survival in patients based on H...

Cur síos iomlán

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Robert L. Hollis (15034814) (author)
Rannpháirtithe:	Alison M. Meynert (14956260) (author), Caroline O. Michie (15043392) (author), Tzyvia Rye (4733277) (author), Michael Churchman (15034811) (author), Amelia Hallas-Potts (15043395) (author), Ian Croy (15034823) (author), W. Glenn McCluggage (8775452) (author), Alistair R.W. Williams (15043398) (author), Clare Bartos (15034820) (author), Yasushi Iida (4097272) (author), Aikou Okamoto (14957624) (author), Brian Dougherty (108958) (author), J. Carl Barrett (11900099) (author), Ruth March (73809) (author), Athena Matakidou (15034847) (author), Patricia Roxburgh (14961464) (author), Colin A. Semple (15034853) (author), D. Paul Harkin (14873531) (author), Richard Kennedy (248483) (author), C. Simon Herrington (15034817) (author), Charlie Gourley (15034850) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Cancer Biology Tumor Biology Therapeutic Research and Development Clinical Research and Trials Gynecological Cancers Ovarian cancer Oncogenes & Tumor Suppressors BRCA family Precision Medicine Translational Research Tumor Microenvironment Immune cells and the microenvironment
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
de réir: Robert L. Hollis (15034814)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
de réir: Jennifer L. Cotton (17315204)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
de réir: Kankan Cao (16437263)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Supplementary Video from Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma
de réir: Laura Privitera (16015972)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
de réir: Alexander N. Shoushtari (15023909)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
de réir: Anita L. Ray (15313398)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer
de réir: Anita L. Ray (15313398)
Foilsithe / Cruthaithe: (2025)

Tables 2 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
de réir: Simon P. Beyaert (17141915)
Foilsithe / Cruthaithe: (2025)

Tables 3 from Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111–24111)
de réir: Simon P. Beyaert (17141915)
Foilsithe / Cruthaithe: (2025)

Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
de réir: Robin M. Hallett (15037427)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables ST1-ST6 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
de réir: Robin M. Hallett (15037427)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 1 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
de réir: Patrizia Mondello (15045002)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 2 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
de réir: Patrizia Mondello (15045002)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
de réir: Patrizia Mondello (15045002)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure 4 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies
de réir: Patrizia Mondello (15045002)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_9db9f9teaeqolr9mdgnmmrk60j